Han Q X
Cancer Hospital, Shanghai Medical University.
Zhonghua Wai Ke Za Zhi. 1992 May;30(5):287-9, 317.
From Jan. 1978 to Dec. 1987, 221 patients of stage III breast cancer were treated by surgery combined with adjuvant chemotherapy and/or radiation therapy. The overall 5-year survival rate was 50.4%. The 5-year survival rate in patients with negative lymph node was 72.3% as compared with 37.5% in patients with more than 7 lymph nodes involved (P < 0.05). In patients who received postoperative adjuvant chemotherapy, the 5-year survival rate in premenopausal or postmenopausal group was 62.1% and 41.4% respectively (P < 0.05). The regional lymph node recurrence rate was 4.0% in patients who received postoperative radiotherapy as opposed to 9.6% for those without radiotherapy postoperatively. The distant metastasis rate was 19.1% in lymph node negative group as compared with 45.9% in patients with more than 7 lymph nodes involved (P < 0.05). To decrease the distant metastasis will improve the survival rate in the treatment of breast cancer. We believe that preoperative chemotherapy combined with radical surgery and postoperative adjuvant therapy may improve the survival rate in stage III breast cancer.
1978年1月至1987年12月，221例III期乳腺癌患者接受了手术联合辅助化疗和/或放疗。总体5年生存率为50.4%。淋巴结阴性患者的5年生存率为72.3%，而淋巴结受累超过7个的患者为37.5%（P<0.05）。接受术后辅助化疗的患者中，绝经前或绝经后组的5年生存率分别为62.1%和41.4%（P<0.05）。接受术后放疗的患者区域淋巴结复发率为4.0%，而术后未放疗的患者为9.6%。淋巴结阴性组的远处转移率为19.1%，而淋巴结受累超过7个的患者为45.9%（P<0.05）。降低远处转移将提高乳腺癌治疗的生存率。我们认为术前化疗联合根治性手术及术后辅助治疗可能提高III期乳腺癌的生存率。
